I was planning on waiting for the official announcement by ApoPharma, but the Cooley's Anemia Foundation has announced it on their site. I learned this past weekend that Ferriprox (deferiprone, L1) is being submitted for approval to the FDA in the US. After so many delays and while most of the rest of the world has approved L1 and after over 20 years of use in India as Kelfer, we finally see a light at the end of the tunnel.
This site was one of the very first sites online to campaign for the approval of L1 in the US. This dates back to my early involvement at the MSN site and perhaps only Ashish had pre-dated this site in its support for providing the iron chelator L1 in the US. Lisa was on a trial in Philadelphia during the 90's but the bad science that was accepted as fact in the Toronto trials put an end to trials in North America. Lisa flat out told me that she believed the one thing that could save her life was taken away. After all these years, the one chelator that has been proven to be the superior chelator of cardiac iron is finally going to get a chance for FDA approval. This is very timely, as more and more reports are coming in from older patients who have found they cannot use Exjade. Exjade has been promoted as the chelation solution that everyone was waiting for, but I will not be surprised if eventually it loses its prominence in the market as safer and more effective chelators are developed. Frankly, if you have a history of kidney or liver illness, you should be very careful about choosing Exjade and be monitored very closely if you are using it.
Ferrirpox will bring a choice to the patients in the US that is needed, and hopefully we will also see the approval of the Ferriprox oral solution. The oral solution is the ultimate in ease of administration of a chelator and the occurrence of nausea has dropped to 1% with the oral, compared to 16% with the Ferriprox tabs. Only with a variety of chelators can all patients have a chance to survive, and what doctors believe is that you should not plan on spending your entire life on one chelator because they all have long term effects that can be avoided if patients have access to a full choice of chelators. As a long supporter of L1, I am personally very happy about this development and I know my efforts have played a small part in this day's arrival. I wish it had arrived years ago, so many patients could have had a chance to live. Time to move forward.